Sangamo Biosciences Prices its $65M Public Offering

By Catherine ShafferStaff Writer

Wednesday, September 18, 2013

Sangamo Biosciences Inc. will collect about $65 million in gross proceeds from a public offering of 6. 1 million shares of common stock in an underwritten public offering. The company will funnel the money into continued research and development of its engineered zinc finger DNA-binding proteins (ZFP).